PROF vs. OBIO, CVRX, ARAY, QIPT, DRTS, CLPT, DCTH, RCEL, ANGO, and UTMD
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include Orchestra BioMed (OBIO), CVRx (CVRX), Accuray (ARAY), Quipt Home Medical (QIPT), Alpha Tau Medical (DRTS), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), AVITA Medical (RCEL), AngioDynamics (ANGO), and Utah Medical Products (UTMD). These companies are all part of the "surgical & medical instruments" industry.
Profound Medical (NASDAQ:PROF) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
In the previous week, Profound Medical had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 9 mentions for Profound Medical and 7 mentions for Orchestra BioMed. Profound Medical's average media sentiment score of 0.92 beat Orchestra BioMed's score of 0.60 indicating that Profound Medical is being referred to more favorably in the media.
Profound Medical received 31 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 71.15% of users gave Profound Medical an outperform vote.
Profound Medical has higher revenue and earnings than Orchestra BioMed. Profound Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Profound Medical currently has a consensus target price of $14.58, suggesting a potential upside of 67.05%. Orchestra BioMed has a consensus target price of $17.00, suggesting a potential upside of 242.05%. Given Orchestra BioMed's higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Profound Medical.
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 6.7% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profound Medical has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Profound Medical has a net margin of -386.63% compared to Orchestra BioMed's net margin of -2,330.46%. Orchestra BioMed's return on equity of -65.33% beat Profound Medical's return on equity.
Summary
Profound Medical and Orchestra BioMed tied by winning 9 of the 18 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
